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We are facing a global epidemic of obesity and type 2 diabetes. Weight loss, in the con-
text of obesity and type 2 diabetes, may improve glycaemic control and weight‐related
comorbidities, and in some cases, induce diabetes remission. Although lifestyle‐based
weight loss strategies may be initially successful, most are not effective long‐term. There
is an increasing need to consider pharmacological approaches to assist weight loss in
diabetes‐obesity. Older glucose‐lowering agents may cause weight gain, whereas the
newer drug classes, sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) and glucagon‐
like peptide receptor agonists (GLP‐1 RAs), concomitantly target weight loss and
glycaemic control. Clinical trial data suggest that both SGLT2i and GLP1 RAs cause a
mean weight loss of approximately 2 to 3 kg but real‐world evidence and clinical experi-
ence suggests a significant heterogeneity in themagnitude of the weight loss (GLP‐1 RAs)
or the magnitude of the actual weight loss is significantly less than anticipated (SGLT2i).
Why do some individuals lose more weight than others in response to these pharmaco-
logical treatments? This reviewwill first exploremechanisms bywhich bodyweight is reg-
ulated through control of energy balance and its dysregulation in obesity, and then
consider how these mechanisms maybe modulated therapeutically with SGLT2i and
GLP1 RAs.
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Obesity has a critical role in the development and progression of type
2 diabetes (T2DM). With the rising prevalence of obesity, the excess
risk of T2DM with even modest weight gain is significant, increasing
exponentially relative to body mass index (BMI), in men and women.1,2- - - - - - - - - - - - - - - - - - - - - - - - - - -
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with a 42‐ and 93‐fold increased risk, respectively.3
The pathophysiology of T2DM is thought to be mediated by
ectopic fat deposition (in visceral fat, skeletal muscle, liver, pancreatic
β‐cells, and other organs), as subcutaneous fat expansion becomes- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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2 BROWN ET AL.saturated, leading to hepatic and peripheral insulin resistance and pro-
gressive β‐cell failure, ultimately leading to hyperglycaemia.4 Weight
loss is critically important to prevent such ectopic fat deposition,
exemplified by the finding that in the Diabetes Prevention Program,
every 1 kg weight loss was associated with a 16% relative risk reduc-
tion in individuals progressing from impaired glucose tolerance to
T2DM.5 In T2DM, even moderate weight loss (3%‐5%) has significant
health benefits, beyond improving glycaemic control, improving other
weight‐related comorbidities in a dose‐dependent manner.6 This is
best mechanistically illustrated by the rapid improvement in glucose
homeostasis in patients with T2DM with a low calorie diet. The dra-
matic and rapid metabolic improvement preceding any significant
weight loss is explained by mobilization of liver fat (reducing hepatic
glucose output with enhanced hepatic insulin resistance) and mobiliza-
tion of pancreatic fat (restoring first phase of insulin secretory
response).7 Longer‐term results from individuals following bariatric
surgery show that this is associated with long‐term remission of
T2DM, a reduced incidence of microvascular and macrovascular com-
plications and reduced mortality.8,9 Currently, however, only a minor-
ity will have access to either of these interventions, with other
structured interventions difficult to implement in clinical practice.
The typical trajectory of weight change with a lifestyle interven-
tion (eg, diet, exercise, and behaviour change) is characterized by early
weight loss, plateauing at around 6 months, followed by an insidious
and progressive weight gain over the following months.10 When clin-
ically appropriate, there is increasing attention towards pharmacologi-
cal approaches, with reinvigorated efforts to reinforce and implement
lifestyle changes, to assist weight loss over the longer term. There has
been a disappointing history of effective therapies for weight loss,
with a number of agents being withdrawn following their approval,TABLE 1 Weight change achieved in published Phase III trials with avail
glucose co‐transporter 2 inhibitors (SGLT2i)
Drug Properties
GLP‐1 RA
Dulaglutide GLP‐1 RA peptide fused to
IgG4 molecule
Exenatide 39 AA peptide
Exenatide‐QW Encapsulated in biodegradable
polymer microspheres
Liraglutide C‐16 fatty acid to lys26, non‐
covalent bond to albumin
Liraglutide C‐16 fatty acid to lys26, non‐
covalent bond to albumin
Lixisenatide 44 AA derivative of exenatide





Abbreviations: bd, twice daily; od, once daily; po, oral; sc, subcutaneous. These
to indicate comparative efficacy.including sibutramine (increased risk of adverse cardiovascular events)
and rimonobant (mood disorders and suicidal ideation). Currently, five
anti‐obesity drugs have been approved by the US Food and Drug
Administration (FDA): (1) combination of phentermine and topiramate,
(2) 5‐hydroxytryptamine2C (5‐HT2C) serotonin receptor agonist
lorcaserin, (3) naltrexone/bupropion, (4) liraglutide 3.0 mg, and (5)
orlistat, but only the latter three are available in Europe. Older
glucose‐lowering therapies (sulfonylureas, thiazolidenediones, and
insulin) can exacerbate weight gain11 but the newer glucose‐lowering
therapies such as glucagon‐like peptide receptor agonists (GLP‐1 RAs)
and sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) can further
enhance weight loss, concomitantly lowering HbA1c and body weight.
However, despite contrasting modes of action to reduce body weight,
both drug classes are associated with highly variable weight loss and
their weight‐lowering effect unpredictable (Table 1).
Weight loss variability between individuals in response to SGLT2i
or GLP‐1 RAs is clearly not explained wholly by heterogeneity in the
pharmacological response. Ongoing mechanistic studies and further
clinical experience of these agents, alone and in combination in differ-
ent populations, will provide insight into the physiological, psycholog-
ical, and pharmacogenetic basis for weight loss variability. A better
understanding of the mechanisms involved and the possibility to pre-
dict treatment outcomes could lead to a change in patient treatment
and help optimize outcomes. This review will consider the variability
of the specific metabolic and appetitive adaptations that may attenu-
ate weight loss with SGLT2i and provide possible mechanistic insight
for weight loss variability with GLP1 RAs. However, we emphasize
that the physiological basis for weight loss variability is likely generic
across all weight loss interventions, be it achieved through lifestyle,
pharmacological, or surgical interventions.able glucagon‐like peptide receptor agonists (GLP‐1 RAs) and sodium‐
Route of
Administartion/Dosing
Weight Change in T2DM
Trials: Absolute (kg)
sc 0.75‐1.5 mg weekly −0.8 to 2.912
sc 5‐10mcg bd −1.4 to 413-18
sc 2 mg weekly −1.6 to 3.712,13,18
sc 1.2 mg‐1.8 mg od −2 to 5.011,14,19-21
sc titrate in 0.6 mg weekly
increments to 3 mg od
−6.019
sc 10‐20mcg od −1.3 to 3.015
po 100‐300 mg od −2.5 to 4.022,23
po 5‐10 mg od −2.65 to 3.224-27
po 10‐25 mg od −2.08 to 2.528,29
po 5‐10 mg od −2.5 to 3.530-32
data are from separately published studies and, therefore, are not intended
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BODY WEIGHT
2.1 | When weight is stable
When weight is stable, it is maintained by a dynamic equilibrium
involving regulation of energy intake and of energy expenditure.
Appetite/energy intake is controlled by homeostatic mechanisms
(based on nutrient/energy requirements during periods of fasting)
and hedonic mechanisms (based on desire for palatable food driven
by pleasurable properties, incorporating sight, smell, and taste, rather
than metabolic need), with interaction with environmental factors
(Figure 1). The two mechanisms are interrelated and synergistic.
Homeostatic mechanisms depend on efferent signals (eg, leptin) from
long‐term tissue stores, especially adipose tissue, and episodic signals
(eg, GLP‐1); arising largely from the gastrointestinal (GI) tract gener-
ated by eating, relaying information to the brain, mainly to the hypo-
thalamus. We also know that variables other than energy intake and
satiety have a profound effect on food intake, such as the pleasurable
(hedonic) properties of food. Hedonic appetite is mediated through a
central reward pathway, predominantly driven by dopamine and opi-
oid transmission in the striatum.332.2 | With weight gain
In obesity/weight gain, not only is there a homeostatic deficit (reduced
satiety or fullness) but this is also potentially coupled with an overac-
tive hedonic/reward system (failure of satiety to impact on hunger
responsiveness to food cues), with a resulting preference for energy‐
dense food and potentially greater influence from environmental fac-
tors.34 For example, if you have ever eaten a piece of chocolate cake,FIGURE 1 Interaction between biology and
environment in the control of energy intake in
body weight [Colour figure can be viewed at
wileyonlinelibrary.com]even though you might feel completely “full,” your reward system
overrides the homeostatic system, encouraging you to eat the cake.
Various factors control the different domains of energy expendi-
ture influencing the basal metabolic rate, oxidation rate, and amount
of physical activity. Individuals who are more likely to gain weight
have lower basal metabolic rates and rates of fat oxidation35,36 and
lower levels of physical activity.2.3 | With weight loss
So what are the caloric equivalents of weight loss? Ultimately, weight
change is caused by a long‐lasting imbalance of food intake and
energy expenditure. It was suggested that a cumulative energy deficit
of 3500 kcal is required per pound (0.45 kg) of body weight loss,37
assuming exclusive loss of body fat. What this simplistic rule fails to
consider are the physiological adaptations, which occur with altered
body weight, specifically with changes in body composition. A poten-
tial confounder in achieving and sustaining weight loss is that energy
expenditure decreases with weight loss. Coupled with a potentially
heightened homeostatic and hedonic regulation of appetite, all of
these biological mechanisms exert their effects preventing further
weight loss and promoting weight regain.
During weight loss, loss of lean tissue/fat free mass (FFM) rather
than fat mass may also exacerbate the gap between energy intake and
energy expenditure. Although less energy is stored in lean tissue than
in body fat (5‐fold higher for fat),38 lean tissue consumes more energy
than fat tissue and thus contributes more to total energy expenditure.39
An important objective duringweight loss is tomaximize the loss of body
fat while minimizing the loss of metabolically active fat‐free mass. When
lean tissue is lost as opposed to fat, total energy expenditure decreases to
a greater extent, making further weight loss more difficult. Hall et al have
attempted to explain the large inter‐individual variability in weight
4 BROWN ET AL.change that occurs during a period of caloric restriction or energy deficit
bymathematically modelling weight loss during a period of energy imbal-
ance (specifically negative energy balance).40
Slowing of resting metabolic rate, beyond that expected from
changes in body composition, is a known phenomenon in weight loss. It
is a potentially adaptive mechanism to counterbalance weight loss and
possibly contributes to weight regain over a sustained period. Measure-
ment of resting metabolic rate (RMR) in participants of the American
TV show, “The Biggest Loser” competition, demonstrated that those with
the greatest weight loss also experienced the greatest slowing of RMR at
the time, despite preservation of FFM.41 Interestingly, long‐term follow‐
up (6 years) of the same participants showed that despite substantial
weight regain in most subjects, a sustained metabolic slowing was
seen.42 Rather counterintuitively, the degree of metabolic adaptation
was not associated with weight regain, but those with a greater long‐
term weight loss had a greater ongoing metabolic slowing with no signif-
icant correlation with changes in hormonal signalling.
Alongside the wider health benefits of exercise, it might be expected
to increasemusclemass43 and preserve RMRduringweight loss,44 in par-
ticular with resistance training. In reality, long‐term compliance to exer-
cise is poor, and even when participants are monitored closely, limited
studies have shown that exercise did not prevent a fall in RMR, despite
relative preservation of FFM,41 with compensatory increases in energy
intake commonly reported, although with high inter‐variability.45
At the same time, metabolic inflexibility may be observed. Usually,
during fasting conditions or high fat intake, there is a high rate of lipid oxi-
dation (with high rates of fatty acid uptake) for energy production, while
under insulin‐stimulated or fed conditions, there is suppression of lipid
oxidation, increased glucose uptake, oxidation, and storage.46 With met-
abolic inflexibility, we observe dual defects: under fasting conditions,
diminished fatty acid oxidation leading to positive fat balance, while in
the postprandial state (when glucose is the predominant fuel), an inability
to switch to glucose metabolism. Metabolic inflexibility has been shown
to predict future weight gain.35,36 Patients with obesity who then lose
weight have lower rates of fat oxidation with those successful at main-
taining weight loss long‐term (responders) having higher oxidation rates
than those experiencing weight regain (non‐responders).47-49
During periods of negative energy balance and reduced energy
stores (weight loss), attempts are made to maintain homeostasis throughhormonal signalling (eg, leptin and insulin) and other afferent neuronal
signals relaying information to the brain (hypothalamus) to stimulate
appetite and promote weight gain. An important finding is that many of
these hormonal alterations persist for 12 months or more after weight
loss, even after weight regain.50 Coupled with a potentially heightened
hedonic drive for consumption of highly palatable energy‐dense food,
this may completely overwhelm the homeostatic system driving further
food intake even when there is no metabolic need, hampering long‐term
weight loss. Measuring eating behaviour and appetite can be challenging
and inaccurate. Energy intake in the DIRECT study, comparing low fat
versus low carbohydrate diets, was incorrectly believed to be unchanged
based on a 24‐hour recall and questionnaires leading to the assumption
that bodyweight plateau and weight regain was a result of change in
energy expenditure only.51 Using a validated mathematical modelling to
determine energy intake, it can be clearly seen that the reductions in
energy intake progressively subside,52 either through lack of compliance,
or compensatory changes in appetite.
Taken together, to accurately predict weight loss with any life-
style or pharmacological intervention imposing an energy deficit, one
must factor in initial body weight and body composition, differential
mobilization of fat versus lean tissue with progressive weight change
leading to dynamic changes in resting metabolic rate and substrate
oxidation, and compensatory changes in appetite that may occur.3 | RESPONDERS VERSUS
NONRESPONDERS
The concept of “responders” and “non‐responders” applies to any
physiological outcome with any intervention, eg, change in HbA1c
with glucose‐lowering therapies, or changes in V02 max with exercise
training. Clinical trial data reporting mean weight loss as an outcome
measure conceal the heterogeneity of weight change, with significant
vs. absent/negligible weight loss giving rise to responder (defined as
greater than or equal to 5% weight loss) vs. non‐responder populations
(defined as less than or equal to 5% weight loss). However, it should
be recognized that the response is not dichotomous and usually fol-
lows a normal distribution curve that is shifted to the left or right
depending on the intervention (Figure 2).FIGURE 2 Graphical representation of
potential weight loss variability achieved with
a weight loss drug [Colour figure can be
viewed at wileyonlinelibrary.com]
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ping rules” based on responder analyses, stipulating thresholds when
pharmacotherapy should be discontinued if clinically relevant weight
loss has not occurred (based on risk/benefit and cost). Several studies
have attempted to explain the heterogeneity in weight change by
stratification of weight loss: responders (greater than or equal to 5%
weight loss) and non‐responders (less than or equal to 5% body weight
loss).53,54 Others have identified three levels of response: responders
(more than 5% weight loss), non‐responders (less than 5% weight loss),
and those who gained weight.55 In such cases, additional phenotype
(eg, early weight loss), psychological and physiological adaptations,
were discussed but no firm conclusions were drawn.
Obesity represents a chronic disease, and the critical consider-
ation during a weight loss intervention is not only the short‐
medium–term weight loss (3‐6 months) but also longer‐term
maintenance of weight loss (1‐2 years or more). After weight loss,
rates of recidivism are universally high with many suggesting that
there are compensatory mechanisms involved to defend a weight
“set‐point” and resist weight loss. Should physicians discontinue drug
therapy in apparent non‐responders, minimizing side effects from inef-
fective treatment and rationalizing scarce health resources more strin-
gently, or is this an opportunity to intensify treatment? There is little
consensus on how to treat patients who reached the initial milestones
but later plateau or indeed gain weight. Further research is required to
optimize long‐term weight loss strategies, particularly in individuals
with T2DM.4 | TREATMENT VARIABILITY
A complex interplay of non‐biological and biological factors may
explain treatment variability (Figure 3).
The differential ways in which an, “obesogenic environment” may
influence obesity‐promoting behaviour (eg, eat more, do less) amongFIGURE 3 Potential physiological,
psychological, and genetic factors that may
explain weight change variability with any
drug intervention [Colour figure can be
viewed at wileyonlinelibrary.com]individuals is not fully understood.56 An almost overwhelming number
of non‐biological factors in our circumstances and environment com-
bine together to determine our health. Determinants of weight may
include the social and economic environment (eg, income, education,
and employment), the physical environment (eg, food availability and
safe areas for physical activity), and access to healthcare. Could it be
that “non‐response” in some people is simply because of the
obesogenic environment counteracting any therapeutic attempt of
weight loss? Some individuals may be better than others at resisting
such an environment. Implementation of policies that prioritize
healthy food environments and systems is beyond the scope of this
review but warrants significant consideration.
Compliance with the prescribed medication or the concomitant
prescribing of multiple glucose‐lowering agents, which counteract
the desired weight loss should also be considered. There would be
lesser weight loss in patients taking concomitant sulfonylureas,
thiazolidinediones, and insulin, agents usually associated with weight
gain, compared with those not taking such agents. For example, the
relative efficacy of the weight loss effects observed with the SGLT2i
dapagliflozin in real world evidence (approximately 6 kg) compared
with a smaller effect in clinical trials (approximately 2‐3 kg) in T2DM,
may reflect lower real world use of agents associated with weight gain,
such as sulfonylureas and/or insulin, and a higher relative use of
metformin.57
Biological determinants of weight loss response can be broadly
split into genetic and non‐genetic factors. Given the high heritability
of obesity (approximately 40%‐70%),58 this field has attracted much
interest. Genetic predisposition in most people is polygenic, with each
individual genetic variant having only subtle effects; although cumula-
tively the effect on BMI is much greater. It seems logical to consider
genetics in the context of response to treatments and weight loss.
One example comes from the Preventing Overweight Using Novel
Dietary Strategies (POUNDS LOST) trial, in which carriers of the fat
mass and obesity‐associated gene (FTO) variant risk allele lost weight
6 BROWN ET AL.more successfully on a high‐protein than on a low‐protein diet.59
Despite promising advances in the pharmacogenomics of T2DM, some
results have been conflicting, with difficulty translating findings to
suggest any specific genetic polymorphisms are associated with a dif-
ferential clinical effect at this stage.60 Response to pharmacotherapy
may vary due to a number of broader characteristics such as demo-
graphics (age, gender, ethnicity, body mass index), psychological traits,
or comorbidities.61-64 Despite this, patients with apparently similar
phenotypes do not always achieve the same weight change.5 | GLP‐1 RECEPTOR AGONISTS
Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone secreted from
the L‐cells in the small intestine, increasing pancreatic β‐cells' insulin
secretion (in a glucose dependent manner) and inhibiting hepatic glu-
cose production via reduced α‐cell glucagon secretion.65,66 GLP‐1 is
a physiological regulator of appetite and food intake via the central
GLP‐1 receptors, mediating reduced appetite and weight loss.67,68
Administration of GLP‐1 to rats into key mesolimbic structures (ven-
tral segmental area and nucleus accumbens) resulted in decreased
motivated behaviour for sucrose in rats, eg, reduction in how hard
the rat was willing to work for a sweet reward.69 Conversely, blocking
the GLP‐1 receptor increases food intake in satiated rats.70
Currently, available GLP‐1 RAs in Europe include exenatide b.d.
and weekly, liraglutide; and more recently, lixisenatide and
dulaglutide.
A meta‐analysis of 21 trials of patients who were overweight or
with obesity, with or without T2DM, treated with a GLP‐1 RA
(exenatide twice daily, exenatide once weekly, or liraglutide up to
1.8 mg) showed a weighted mean difference in body weight of
−2.9 kg, achieved with the highest dose of GLP‐1 RAs compared with
the control treatment (placebo, oral antidiabetic drugs, or insulin).71
Weight loss in the GLP‐1 RA groups for patients without diabetes
(−3.2 kg, −4.3 to −2.1; three trials) as well as patients with diabetes
(−2.8 kg, −3.4 to −2.3; 18 trials) was demonstrated.
More recently, liraglutide 3.0 mg, tested as an adjunct to a
reduced calorie diet and increased physical activity, has been studied
in pre‐diabetes and people with diabetes in the Satiety and Clinical
Adiposity Liraglutide Evidence in (SCALE) phase III studies. Depending
on the study, participants experienced a dose‐dependent weight loss
ranging between 5.7% and 9.2% (6.0‐8.8 kg), whereas subjects treated
with placebo (on diet and exercise alone) had a mean weight loss
between 0.2% and 3.1% (0.2‐3.0 kg).20,72 Liraglutide 3.0 mg once
daily, combined with diet and exercise, also was able to significantly
enhance the weight loss achieved with a low calorie diet (LCD), an
estimated further reduction of 6% of body weight versus an LCD
alone (with placebo).73 Semaglutide, a novel once weekly injectable
GLP‐1 RA has been studied in people with diabetes in a series of
SUSTAIN studies, with marked dose‐dependent weight loss
observed.74-77 In a phase II trial in patients with obesity only, doses
of 0.2 mg day−1 or more resulted in clinically meaningful weight loss
compared with placebo and higher than liraglutide 3.0 g day−1;0.4 mg day−1 of once daily semaglutide was associated with a weight
loss of −15.15 kg (estimated percentage weight loss change −13.8%)
from a baseline of 113.2 kg.78
Despite the considerable efficacy, there is considerable heteroge-
neity in their weight‐lowering effect. Perhaps not surprisingly, early
weight loss in treatment has been identified as a key predictor of suc-
cess with the variable response to GLP‐1 RA apparent as early as
4 weeks in some trials.55 In the weight management programme scale
less than or equal to 4% weight loss (responder) at week 16, with
liraglutide 3.0 mg, was a strong predictor of clinically meaningful
weight loss after 1 year. Early responders without T2DM achieved
mean weight loss of 10.8% (11.2 kg) compared with early non‐
responders (less than 4% weight loss from baseline at W16) without
T2DM, losing 3.0% (3.2 kg) at week 56. Early responders with T2DM
achieved mean weight loss of 8.5% (9.0 kg) at week 56, while early
non‐responders with T2DM only lost 3.1% (3.2 kg) at week 56.535.1 | Potential biological mechanisms underpinning
weight loss heterogeneity with GLP‐1 RAs
5.1.1 | Effect of gender and baseline weight
In the liraglutide 3.0 mg clinical development programme, weight loss
and glycaemia improvement were dose‐dependent with higher doses
required for maximum weight reduction.20,72 There was a tendency
for greater weight loss in females versus males, and less weight loss
in subjects with a BMI > 40 kg m2.
5.1.2 | Pharmacokinetic factors
Limited head‐to‐head studies of GLP‐1 RAs suggest that semaglutide
and liraglutide are most effective for weight loss, whereas weight loss
is somewhat less with albiglutide,12-16,19,21,79-81 perhaps because the
albumin component of this drug limits its ability to reach the central
nervous system.21
Population pharmacokinetic analysis of liraglutide up to 3.0 mg in
non‐diabetic and diabetic people have demonstrated a clear exposure‐
response relationship between liraglutide and body weight reduction,
suggesting that differences in response to treatment may be associ-
ated with differences in exposure.82-84 Body weight and sex were rel-
evant factors for the exposure level of liraglutide.82,83 Higher body
weight was associated with decreased liraglutide exposure. Liraglutide
exposure was 32% higher in females than in males of comparable body
weight.82 Women had greater weight loss than men at similar expo-
sures, although the absolute weight loss in all subgroups was clinically
meaningful with increasing exposure associated with increasing
weight loss.84
5.1.3 | Polymorphisms in the GLP‐1 receptor
Pharmacogenetic studies on GLP‐1 RA are limited. Genetic variability in
GLP‐1 receptor has been demonstrated to be associated with inter‐
individual differences in weight lowering potential with liraglutide in
BROWN ET AL. 7T2DM (gene variant: rs6923761)85 and in women with obesity and
PCOS (gene variant: rs10305420).86 Among these genetic variants,
the T2DM associated variants in TCF7L2 (gene variant: rs7903146)
and WFS1 (Wolfram Syndrome 1) have been shown to affect the
response to exogenous GLP‐1, while variants in KCNQ1 (gene variants:
rs151290, rs2237892, and rs2237895) have been reported to alter
endogenous GLP‐1 secretion.87-895.1.4 | Variability of CNS food‐related responses to
GLP‐1 RA action
Using functional magnetic resonance imaging (fMRI) several studies in
individuals with obesity have demonstrated increased activation in
appetite‐ and reward‐related brain areas (eg, amygdala, nucleus
accumbens, insula, and orbitofrontal cortex) in response to viewing
food cues,90 and this increased food cue responsiveness predicted
weight gain.91 Interestingly, GLP‐1 receptor activation reduces brain
response (ie, in insula, amygdala, putamen, and orbitofrontal cortex)
to food cues in subjects with obesity, with and without T2DM, corre-
lating with reductions in food intake.92
These findings are useful when considering response to treatment
in clinical practice, but they do not look at the differences in response
to understand the weight change variability between weight
responders and non‐responders to treatment. Attempts to dissect
the homeostatic and hedonic components of appetite would be helpful
to define how GLP‐1 RAs affect each, and which component is “resis-
tant” in patients who do not lose weight. Further human functional
neuroimaging studies, before and after GLP‐1 RA therapy, determining
whether there are differential effects of GLP‐1 RAs on the ability to
modulate CNS food‐related responses in responders vs. non‐
responders after short‐ to medium‐term treatment, may provide
insight into the biological mechanisms underlying weight loss variabil-
ity with treatment.6 | SODIUM‐GLUCOSE CO‐TRANSPORTER
2 INHIBITORS (SGLT2I)
It is widely accepted that the sodium‐dependent glucose
co‐transporter proteins 1 and 2 (SGLT1/2) regulate renal glucose reab-
sorption in the proximal renal tubule of the kidney: approximately 90%
by SGLT2 with the SGLT1 transporter, in the distal segment, responsi-
ble for the remaining 10%.93 InT2DM, there is paradoxically excessive
renal glucose reabsorption exacerbating hyperglycaemia,94,95 poten-
tially because of upregulation of SGLT2 or SGLT1 or both.95,96 Further
understanding of this is needed in order to maximize glucosuria, but
SGLTi drugs inhibit glucose reabsorption, promoting approximately
75 g of urinary glucose excretion with an associated caloric loss
(approximately 300 kcal day−1), explaining the weight loss.97 There
are currently four SGLT2i available for use within Europe, namely
canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.
Clinical trial data suggest SGLT2i produces a mean weight loss of
approximately 2 to 3 kg in patients with T2DM, irrespective of thebackground therapy (monotherapy,22,24 as add‐on therapy to other
oral agents, eg, metformin,25,26,28,30 sulfonylureas,27,29,98,99 gliptins,100
and insulin101).
In patients with chronic kidney disease (CKD), HbA1c‐lowering
effects of SGLT2 inhibition are consistently reduced because of the
attenuation of glycosuria in the setting of CKD; urinary glucose excre-
tion is about 50% lower in patients with T2DM, with CKD3 treated
with dapagliflozin, compared with patients with normal/mildly
impaired renal function. There is no evidence that variation in urinary
glucose excretion (UGE), independent of renal function, is a factor in
determining weight loss.
Phase II trials have considered SGLT2i in subjects who are over-
weight or with obesity without diabetes (SGLT2i are not currently
licensed for this indication). Weight loss observed over 12 weeks in
one randomized controlled trial (RCT) was relatively modest but signif-
icant (placebo‐subtracted changes for all canagliflozin doses, percent
body weight change less than 2%). Canagliflozin 50, 100, and
300 mg produced approximately 2 to 3 kg of weight loss compared
with baseline, and approximately 1 to 1.5 kg of weight loss compared
with placebo.102
In real‐world data, one observational study in primary care dem-
onstrated a mean weight loss of 2.6 kg (95% CI, 2.3‐2.9) 14 to 90 days
after starting dapagliflozin and 4.6 kg (95% CI, 4.0‐5.2) beyond
180 days.103 Weight loss with SGLT2i generally plateaus after
26 weeks of treatment in patients with T2DM despite sustained
UGE.26,27,296.1 | Possible adaptations to SGLT2i therapy that
limit weight loss
There is great interest as to why SGLT2i therapy is not associated with
more pronounced weight loss considering the caloric loss/energy def-
icit (300 kcal day−1; approximately 1,300 kJ) accompanying the
enhanced glucose excretion (75 g of daily urinary glucose excretion).97
As an energy deficit of 15 MJ week−1 would be expected to be asso-
ciated with a 0.5 kg loss of body weight per week (using the “static
weight loss rule”), the expected weight loss over 24 weeks treatment
with SGLT2i would be approximately 7 kg (assuming no compensatory
changes in energy balance or diuresis).6.1.1 | Compensatory hyperphagia
It has been speculated that the discrepancy between observed and
expected weight loss with SGLT2i may arise because of compensatory
increases in energy intake and changes in energy expenditure that act
to attenuate the energy imbalance. In rodent models, SGLT2 deletion
or chronic treatment with the SGLT2i dapagliflozin resulted in a com-
pensatory increase in caloric intake.104,105 Rats with dietary obesity
lose weight when treated with dapagliflozin (approximately 4%), but
this is associated with a 30% increase in energy intake. Furthermore,
weight loss was four times larger when animals were pair‐fed as com-
pared with ad‐libitum diet.105 Studies using alternative SGLT2i in
8 BROWN ET AL.animals have not demonstrated the same increase in energy intake
(approximately 4%).106,107
Mathematical models based on studies of SGLT2i in patients with
T2DM predict that energy intake after weight loss because of urinary
glucose excretion (UGE) may exceed adaptions in energy expenditure,
contributing to difficulties with sustained weight loss.108,109 In one
study, weight loss was less than a third of that predicted by the model,
with the majority of the difference accounted for by an increase in
energy intake (13%), with a small contribution for diet‐induced
thermogenesis.108
Considering the hormonal and metabolic adaptations that occur
with weight loss (from any intervention) that tries to limit weight gain
and restore body weight back to its previous “set point,” the compen-
satory hyperphagia reported with SGLT2i therapy is in many ways
entirely appropriate.
6.1.2 | Changes in energy expenditure/substrate
utilization
There are a paucity of human interventional data on whole body met-
abolic changes occurring secondary to increased urinary glucose
excretion with SGLT2i. Several publications have shown that the
increased urinary glucose excretion following SGLT2 inhibition is asso-
ciated with a paradoxical increase in endogenous (hepatic) glucose
production108-110 possibly caused by a compensatory release of gluca-
gon from the α‐cells in the pancreatic islets.111 This will partially
negate the SGLT2i effect on glucose concentration, but would not
necessarily modify weight loss.
In SGLT2 knockout, mice food intake was greater, physical activ-
ity increased, energy expenditure was higher, and respiratory quo-
tient fell, consistent with a shift from carbohydrate to fat
metabolism.105 Human studies have demonstrated that chronic
(4 weeks) administration of empagliflozin causes a shift in fuel utiliza-
tion from carbohydrate towards fatty substrates to cause loss of fat
mass and weight loss, but no changes were seen in resting or post-
prandial energy expenditure as measured by indirect calorimetry,
implying that energy intake is increased to explain the discrepancies
in weight loss seen.108
The development of euglycaemic ketoacidosis in T2DM subjects
treated with SGLT2i has been reported. While the underlying mecha-
nism is poorly understood, it is suggestive of complex metabolic adap-
tations taking place. Changes in substrate utilization from glucose to
lipid provides an explanation for increased ketone production with
SGLT2i.108
6.1.3 | Genetic polymorphisms
A large number of genetic polymorphisms have been described affect-
ing the response to treatment with other oral hypoglycaemic agents.
This may explain the inter‐individual response to SGLT2i and there is
an emergence of data regarding genetic variability. In a population
pharmacokinetic model of canagliflozin in diabetic and non‐diabetic
individuals, Hoeben at al reported UGT1A9*3 among several othercovariates to influence the drug's elimination rate.112 Carriers of
reduced function variants UGT1A9*3 had increased plasma concentra-
tions of canagliflozin, although the clinical significance of this is pre-
sumably small. Nonsense and missense mutations in the SCL5A2
gene coding for the glucose transporter SGLT2 cause familial renal gly-
cosuria, characterized by urinary glucose excretion in the presence of
low‐normal glucose levels.113 Interestingly, these individuals appear to
have normal growth and are asymptomatic.114 The presence of normal
blood glucose concentrations, despite significant glycosuria, highlights
that potentially counter‐regulatory mechanisms are being activated to
compensate for the urinary loss.7 | COMBINATION THERAPY WITH
SODIUM‐GLUCOSE CO‐TRANSPORTER 2
INHIBITORS (SGLT2I)
As discussed previously, the anticipated weight loss with SGLT2i is
less than expected, possibly explained by a compensatory increase in
food intake. It therefore seems logical to combine SGLT2i with
anorexigenic drugs.With phentermine
Results of a phase II trial of the combination of phentermine 15 mg
(an appetite suppressant) with canagliflozin 300 mg in individuals
without diabetes showed greater weight loss with combination ther-
apy than with use of either agent alone.115 Over 26 weeks, placebo,
canagliflozin, phentermine, and canagliflozin/phentermine groups had
mean percentage changes in body weight of −0.6%, −1.9%, −4.1%,
and −7.5%, respectively. It will be interesting to see whether this
combined therapeutic approach is also effective in individuals with
diabetes, although phentermine is not currently licensed for use in
Europe.With GLP1‐RAs
On the basis of the known distinct and complementary mechanisms of
action of SGLT2i and GLP‐1 RAs, and in particular the observations
that GLP‐1 RA can both potently inhibit appetite and reduce hepatic
(endogenous) glucose production,116 co‐administration of these two
agents could overcome the two potentially (mal)adaptive compensa-
tory responses that attenuate the weight loss occurring with SGLT2i
alone. Support for this approach with respect to hepatic glucose pro-
duction comes from the findings of Rosenstock et al,117 who noted
that the combination of a DPP‐IV inhibitor with an SGLT2i may sup-
press the latter's pro‐glucagogenic effects.
DURATION‐8, a 28‐week randomized controlled trial, considered
the efficacy and safety of combination therapy with dapagliflozin and
Exenatide QW in T2DM, inadequately controlled by metformin.118
There were significantly greater reductions in absolute weight change
with exenatide plus dapagliflozin (−3.41 kg) versus exenatide
(−1.54 kg) or dapagliflozin (−2.19 kg) alone. While the weight loss with
BROWN ET AL. 9combination of therapy is not additive, rather synergistic, this study
supports the co‐initiation of dapagliflozin and exenatide weekly. More
recently, the AWARD‐10 study demonstrated greater weight loss with
the sequential addition of dulaglutide 1.5 mg to patients treated with
SGLT2i (with or without metformin).119 SGLT2i and GLP‐1 RAs are
already frequently used concomitantly in clinical practice, and in the
future, use of the combination will likely increase. Undoubtedly, real‐
world evidence will emerge on the efficacy of this exciting
combination.8 | FUTURE CLINICAL AND RESEARCH
DIRECTIONS
Why some patients lose a significant amount of weight with any inter-
vention and others lose none at all remains unanswered. Is it that the
intervention in question will always work for group A and never for
group B with identifiable biological predictors explaining this? Or is it
that the individual non‐responder will almost never respond to any
treatment with the primary driver being environmental and social fac-
tors? Studies dissecting the responses seen in weight responders and
non‐responders to treatment may help further target treatment
approaches. With regards to regulation of appetite, it is not known
whether non‐responders to weight loss interventions have a main-
tained hyper‐activation of the reward system to explain weight
change variability and weight regain and whether this mal (adaptive)
response can be “re‐set.”
There is considerable interest in the mechanisms through which
bariatric surgery mediates long‐term weight loss and its wider health
benefits. Efforts to mimic the changes in circulating gut hormones
and neuroendocrine signalling pharmacologically are much sought
after. GLP‐1 is just one product of the preproglucagon gene others,
including oxyntomodulin and glucagon, also have anorectic effects.
There is an array of other gut hormones (cholecystokinin [CKK], pep-
tide YY [3‐36], and pancreatic polypeptide [PP]) and co‐peptides that
act on multiple receptors to control appetite on the horizon. Combina-
tion therapies and co‐peptides that work on multiple receptors seem
likely to improve the clinical outcomes. Phase II studies are beginning
to investigate hybrid molecules, which are mostly aimed at three key
peptide hormone receptors: GLP‐1, glucagon, and glucose‐dependent
insulinotropic polypeptide (GIP) receptors.120,121 Results of a Phase II
trial with a dual GIP‐GLP‐1 RA (LY3298176) demonstrated clinically
meaningful reductions in HbA1c and weight change (−11.3 kg for
15 mg LY3298176) in people with T2DM when compared with pla-
cebo and dulaglutide (−0·4 kg for placebo, −2·7 kg for dulaglutide).119
Metabolic compensations are clearly capable of modifying the
outcome of any weight loss intervention, but this will likely vary
between individuals with data suggesting that it only partially explains
weight loss variability and weight regain. If metabolic compensation,
eg, appetite and energy expenditure does offset a negative energy bal-
ance, interventions to stop this would be beneficial, thereby limiting
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